Start the conversation
Whenever you see a stock that's resisting a broad market sell-off - or that's not getting caught up in a downdraft in its own sector - you've found an investment opportunity that warrants a much closer look.
That's a piece of market wisdom we've shared with you folks before - most recently with Enanta Inc. (Nasdaq: ENTA), a biotech we recommended on Jan. 2. Just four weeks later, on Jan. 31, with the stock already up 15%, we noticed the vaccine-maker's shares were resisting a broad market sell-off that was inflicting particular pain on biotechs. So we urged you to take a closer look.
As of Wednesday's market close, Enanta's shares were up 40% from our initial recommendation price.
This is premium content for Private Briefing subscribers only.